The global conversation around pediatric vision care is shifting rapidly. Today, forward-thinking ECPs like you aren't just looking to slow down myopia—you want solutions that can stop its progression in its tracks. That’s why HOYA is proud to introduce exciting 12-month data for MiYOSMART iQ, an advanced spectacle lens effectively marking the next generation in myopia management. This lens is clinically proven to stop myopia progression¹ for 9 out of 10 children over the first year of wear. With MiYOSMART iQ, you can fundamentally change your treatment conversations, giving you an effective defence against myopia to offer young patients and greater reassurance for their parents that they are being proactive about their children’s vision health.
Product Disclaimer: Approval and availability of MiYOSMART and MiYOSMART iQ spectacle lenses for myopia control vary by country; they are not approved or available for sale in all countries, including the U.S.
Changing the Myopia Conversation with MiYOSMART iQ
Myopia prevalence continues to rise worldwide, creating an urgent public health challenge that demands more proactive intervention. On average, 30% of the world is currently myopic and by 2050, almost 50%—approximately 5 billion people— will be myopic, according to the World Health Organization. Fortunately, MiYOSMART iQ offers several exciting developments in myopia management, backed by recent 12-month data:
- Unprecedented Control Efficacy: At 12 months of use, children aged 4–12 wearing MiYOSMART iQ spectacle lenses showed no myopia progression on average and eye elongation below or comparable to non-myopic eyes, representing the highest myopia-control efficacy reported to date with D.I.M.S. Technology-based spectacle lenses.² ³
- A Breakthrough for Early Intervention: For the first time with D.I.M.S. Technology-based spectacle lenses, MiYOSMART iQ demonstrated myopia control efficacy in children as young as 4 years old, representing a major milestone in early-onset myopia control.² ³ ⁴ ⁵
- Raising the Bar for Older School-Age Children: In children aged 7–12 years, MiYOSMART iQ resulted in an average myopia control efficacy of over 100%—meaning that, on average, the treatment completely stopped myopia progression and slowed eye elongation to a rate below or comparable to what is typically expected in a non-myopic child of the same age—and achieved 94% average reduction in axial elongation, raising the bar in the fight against progressive myopia.² ⁴
Frequently Asked Questions About MiYOSMART iQ
As you prepare to integrate this next-generation technology into your pediatric practice, here are the quick answers to the top questions doctors are asking about MiYOSMART iQ:
Q: How does MiYOSMART iQ build on the original MiYOSMART lens technology?
A: The new spectacle lens design builds on D.I.M.S. Technology with Triple Enhanced Design (TED), featuring key enhancements that drive greater myopia control effectiveness in children⁶, including an extended treatment zone which provides more extensive coverage of the child's peripheral visual field (even with larger frames).
Q: Does “no progression” really mean no progression?
A: Yes, on a cohort level. In the 12-month randomized controlled trial, the average refractive change across the 4–12 age group was +0.046D—meaning that, statistically, myopia progression completely flattened out, and average axial elongation slowed to a rate comparable to non-myopic eyes.
Q: Is MiYOSMART iQ appropriate to prescribe for young children?
A: Absolutely. In fact, it marks a major clinical milestone: for the first time with D.I.M.S. Technology-based lenses, MiYOSMART iQ demonstrated strong myopia control efficacy in children as young as 4 years old, making it an ideal first-line choice for early-onset progressive myopia.
Q: What should ECPs tell parents about MiYOSMART iQ?
A: Focus on the shift from simply slowing down progression to possibly stopping it. Let them know that, instead of just slowing down the rate at which their child's prescription changes, this next-generation lens is clinically proven to stop progression for 9 out of 10 children¹ in the first year, providing a highly safe and effective myopia treatment.
Q: Is MiYOSMART iQ offered in a photochromic or polarized lens option?
A: MiYOSMART iQ is available in clear and Chameleon (photochromic lens) options, offering uninterrupted myopia management and comfort in all light conditions. The MiYOSMART Sunbird (polarized lens) is available using the original D.I.M.S. Technology.
The launch of MiYOSMART iQ marks an exciting development in myopia control, giving your practice a powerful new way to intercept progression early and change a child's visual trajectory for life. Ready to raise the standard of pediatric care for your patients? For more information about MiYOSMART iQ, please contact your local HOYA Vision Care representative. Explore the 12-month clinical data further via the Press Release.